Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Amplia Therapeutics ( (AU:ATX) ) has shared an announcement.
Amplia Therapeutics has entered a second phase of its preclinical research collaboration with Korean drug screening specialist Next & Bio to further investigate the effects of its FAK inhibitor narmafotinib in combination with experimental kRAS inhibitors on patient-derived pancreatic cancer cells. The extension follows encouraging initial data showing narmafotinib’s activity against kRAS-mutant pancreatic cancer models, and the partners will now explore potential synergistic effects with kRAS inhibitors, a new class of drugs under development for several solid tumours. Amplia sees this next stage as an opportunity to strengthen its scientific case for combination therapies in hard-to-treat pancreatic cancer, enhance the clinical and commercial prospects of narmafotinib and potentially broaden partnering opportunities, while Next & Bio leverages its advanced patient-derived cell platform to support the development of new treatment options in an area of high unmet medical need.
The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company developing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, with a particular focus on fibrotic cancers such as pancreatic and ovarian cancer. Its lead candidate, narmafotinib (AMP945), is a highly potent and selective FAK inhibitor currently in clinical trials for advanced pancreatic cancer, where it has already shown improved response rates and progression-free survival when combined with standard chemotherapies.
Average Trading Volume: 1,083,167
Technical Sentiment Signal: Sell
Current Market Cap: A$64.13M
See more insights into ATX stock on TipRanks’ Stock Analysis page.